FDA Extends Routine Seafood Safety Paperwork
Published Date: 6/11/2026
Notice
Summary
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Estimated Annual Recordkeeping Burden: 1.93M Hours
FDA estimates the total annual recordkeeping burden for seafood HACCP activities is 1,930,264 hours. Examples from the estimate include 1,260,000 hours for documenting monitoring of critical control points (Sec. 123.6(c)(7)) and 65,600 hours for import verification activities (Sec. 123.12).
Seafood Processors Must Keep HACCP Records
If you process or import fish or fishery products, you must continue to collect and keep Hazard Analysis and Critical Control Point (HACCP) records under 21 CFR part 123. These records (for example, processing times, temperatures, acidity, monitoring logs) must be reviewed by trained employees and made available for FDA review as provided in Sec. 123.12(c).
No New Monetary Costs for Recordkeeping
FDA states there are no capital costs or operating and maintenance costs associated with this information collection; the submission is a reinstatement of current paperwork. The collection is described as a continuation of existing HACCP recordkeeping rather than adding new monetary costs.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-11760, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
Next: 2026-11763, Cancellation of Previously Scheduled Open Meeting
The Equal Employment Opportunity Commission (EEOC) canceled its June 4, 2026 open meeting because the important decisions were already made by a vote on paper. This means no one needs to attend the meeting, but the new National Enforcement Plan for 2025-2029 and updated reporting instructions are still in effect. No extra costs or delays are expected from this change.